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Abstract: Ciclesonide is a nonhalogenated synthetic inhaled corticosteroid (ICS) that has 
been approved by the US Food and Drug Administration for the treatment of all severities of 
persistent asthma. It is available as a hydrofluroalkane pressurized metered-dose inhaler in two 
strengths, 80 mcg/activation and 160 mcg/activation, with the recommenced dosage being two 
inhalations twice-daily. It is a prodrug that is converted in the lung to its active form, which 
possesses 100-fold greater glucocorticoid-receptor-binding affinity than the parent compound. 
Its relative receptor affinity is similar to budesonide. In clinical studies, ciclesonide was   effective 
in improving pulmonary function, reducing asthma symptoms, and reducing or eliminating the 
need for oral corticosteroids (OCSs). Patients with severe asthma dependent on OCSs and high 
doses of ICSs were able to achieve greater asthma control and reduce or even eliminate the use of 
OCSs when switched to ciclesonide. In comparison with fluticasone propionate and budesonide, 
ciclesonide was demonstrated to be at least as effective in maintaining pulmonary function and 
asthma control. In clinical trials, ciclesonide was well tolerated, with the majority of adverse 
events considered mild or moderate in intensity. It had low systemic bioavailability and no clini-
cally significant hypothalamic–pituitary–adrenal axis suppression at therapeutic doses. Its safety 
profile establishes ciclesonide as an important addition to the currently available ICSs.
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Introduction
Asthma is a chronic inflammatory disease of the airways that results in airway obstruction 
that is thought to be largely reversible. It is characterized by recurrent   episodes of 
wheezing, dyspnea, chest tightness, and coughing. There is a significant health burden 
associated with asthma due to its resultant morbidity, mortality, and cost.
Both national and international guidelines have been developed to improve the 
diagnosis, management, and outcomes of asthma.1,2 For all categories of persistent 
asthma, inhaled corticosteroids (ICSs) are the cornerstone or first-line therapy due to 
their potent anti-inflammatory properties, which primarily result in reduced numbers 
of airway inflammatory cells and their subsequent mediators. Clinically, they reduce 
bronchial hyperreactivity, asthma symptoms, exacerbations, urgent care visits, and 
hospitalizations, while improving lung function and quality of life.
Current guideline recommendations are to treat mild asthma with a low-dose ICS, 
while moderate asthma (patients $12 years) may be treated with either a medium-dose 
ICS or a low-dose ICS with the addition of a long-acting-beta-2-agonist (LABA).1 For 
severe persistent asthma patients, combination therapy with a medium- to high-dose 
ICS plus a LABA is recommended, possibly with the addition of omalizumab or oral Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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corticosteroids (OCS) if control is not achieved. However, it is 
also a guideline recommendation that once control is achieved 
for a period of time (ie, at least 3 months), the ICS dose should 
be titrated downward to the lowest dose possible to maintain 
control. This is to hopefully minimize any systemic absorption 
that might result in potentially adverse effects such as 
hypothalamic–pituitary–adrenal axis (HPA axis) suppression, 
growth retardation in children, decreased bone mineral density, 
cataracts, skin thinning, and easy bruising. ICSs are usually 
well tolerated and considered to be safe at the recommended 
doses. The occurrences of adverse effects are considered to 
be related to both the dose administered and the duration of 
treatment. When treating patients with asthma, the risk/benefit 
of each treatment step (up or down) should be weighed against 
the outcomes associated with uncontrolled asthma.
In keeping with the above philosophy, newer ICSs are 
being developed to address the needs unmet by current 
ICS therapy. Some of the goals in the development of new 
ICSs would be to: improve therapeutic indexes, particularly 
at higher dosages; have less frequent dosing intervals to 
encourage patient adherence; and maintain clinical effective-
ness and potency.
Ciclesonide (CIC) is indicated for the treatment of per-
sistent asthma in patients aged 12 years or older. It is 
available in a hydrofluroalkane pressurized metered-dose 
inhaler (HFA-MDI) in two strengths, 80 mcg/actuation 
and 160 mcg/actuation, administered twice-daily. The 
recommended starting dose for patients receiving as-needed 
inhaled bronchodilators alone is CIC 80 mcg twice-daily 
with a maximum dose of 160 mcg twice-daily. For patients 
receiving inhaled steroids, the starting dose is 80 mcg 
twice-daily to a maximum dose of 320 mcg twice-daily. For 
patients receiving oral corticosteroids, it is recommended 
that patients start at the maximal dose of 320 mcg twice-
daily with taper of oral prednisone no faster than 2.5 mg/day 
on a weekly basis, starting at least 1 week after initiation of 
CIC therapy.3
Pharmacologic features of ciclesonide
Pharmacokinetics
CIC is a nonhalogenated ICS that is available as a HFA-MDI 
in two strengths, 80 mcg/actuation and 160 mcg/actuation, 
and it is administered twice-daily. Like beclomethasone 
dipropionate, it is a prodrug that is converted to its active 
form desisobutyryl-ciclesonide (des-CIC) via esterases in 
the lung, maximizing its local effects. The parent compound 
CIC is inactive with a relatively low glucocorticoid-receptor 
affinity (RRA) of 12. Des-CIC has a 100-fold greater 
relative-glucocorticoid-receptor-binding affinity than CIC 
(RRA = 1200). The potency of an ICS is assessed in terms 
of its relative receptor affinity versus dexamethasone, which 
is assigned a value of 100.4 An ICS with a higher RRA will 
induce a greater anti-inflammatory effect. In comparison 
with other available ICSs, des-CIC’s RRA is between that of 
mometasone fuorate (MF) (which has a RRA of 2300), fluti-
casone propionate (FP) (RRA: 1800), and budesonide (BUD) 
(RRA: 935), and it is similar to beclomethasone monopro-
pionate (17-BMP) (RRA: 1345).5 Increasing the potency 
of a glucocorticoid leads to higher topical efficacy but also 
may lead to more systemic activity and a higher incidence 
of systemic side effects, as the glucocorticoid receptor is 
expressed in almost all tissues and cells.5
ICSs are deposited in the upper airway and the lungs. 
Depending on the formulation and inhaler device, a large 
portion of the drug may be deposited in the oropharynx, 
swallowed, and then absorbed systemically where it can 
contribute to potential adverse effects. It is desirable for 
the oral bioavailability of ICSs to be low so that the drug 
has low systemic absorption from the gastrointestinal tract 
and for there to be extensive first-pass metabolism so that 
the amount of drug that is absorbed is rapidly cleared, 
minimizing systemic effects. CIC has been formulated as a 
solution HFA-MDI, with particles ranging 1.1–2.1 µm, small 
enough to deposit in the small distal airways, which average 
2 µm in size.4 In two studies, one involving healthy subjects 
and a second study involving patients with mild asthma, 
technetium labeled CIC was shown to reach all regions of the 
lung with higher deposition in the peripheral regions than in 
the central region, and higher deposition in the whole lung 
than in the oropharynx.6,7 The inhaled bioavailability of des-
CIC is 52% compared with 17% for FP via DPI, 29% for FP 
via HFA-MDI, 68% for FLU via HFA-MDI, 55%–60% for 
beclomethasone (BDP) via HFA-MDI, and 11% for MF.5
CIC also exhibits low oropharyngeal deposition and 
low activation to des-CIC in the oropharynx.4 Any drug that 
reaches the systemic circulation binds to plasma proteins 
such as albumin and transcortin. Only the free, unbound 
drug is pharmacologically active and capable of suppressing 
endogenous cortisol. If the drug freely dissociates, this is 
not an issue. CIC has the highest degree of protein   binding 
(99%) followed by MF (98%–99%), 17-BMP (98.4%) and FP 
(90%).5
Since there is low oropharyngeal deposition of CIC, 
low activation to des-CIC, and high protein binding, Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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the potential for local and systemic side effects is low. 
Furthermore, any absorbed drug is subjected to nearly 
complete first-pass metabolism. This was demonstrated in 
a study where healthy subjects were given orally a single 
dose of 6.9 mg of labeled CIC and intravenously 0.64 mg, 
and radioactivity was   determined in blood, plasma, urine, 
and feces. Total   radioactivity in the systemic circulation 
was low, and CIC was not detected in any serum sample. 
Serum concentrations of des-CIC were near or below the 
lower limit of quantification, giving a systemic bioavailability 
of ,1% for des-CIC.8 Elimination occurred mostly via the 
feces and was complete by 120 hours after both oral and 
IV administration. Following intravenous administration of 
800 mcg of CIC, the clearances of CIC and des-ciclesonide 
were high (approximately 152 L/h and 228 L/h, respectively).3 
14C-labeled CIC was predominantly excreted in the feces after 
intravenous administration (66%), indicating that excretion 
through bile is the major route of elimination. Approximately 
20% or less of des-CIC was excreted in the urine. The mean 
half-life of CIC and des-CIC was 0.71 hours and 6–7 hours, 
respectively. Tmax of des-CIC occurs at 1.04 hours following 
inhalation of CIC.3
CIC has several favorable properties, including its 
prodrug structure, high-lipid affinity and glucocorticoid 
receptor-binding affinity of the active drug des-CIC, low 
oral deposition and bioavailability, extensive peripheral 
distribution in the lung, high protein-binding, and extensive 
first-pass metabolism. These properties may lead to a higher 
therapeutic efficacy and lower systemic exposure, thereby 
minimizing potential systemic effects.
Pharmacodynamics
CIC has been shown to have anti-inflammatory effects in vitro, 
with des-CIC conferring even greater anti-inflammatory 
activity. CIC and/or des-CIC were effective in inhibiting 
proinflammatory functions, including the stimulated 
expression of intracellular adhesion molecule-1, and 
stimulated release of inflammatory mediators such as 
granulocyte-macrophage colony-stimulating factor, 
monocyte chemoattractant protein (MCP)-1, interferon-
gamma, interleukin (IL)-2, IL-4, IL-5, IL-8, and tumor 
necrosis factor (TNF)-a. CIC and des-CIC inhibited the 
induced proliferation of immune cells such as peripheral 
blood mononuclear cells, CD4 lymphocytes, and human 
airway smooth muscle cells.9–11
In a small trial of patients with mild persistent asthma, 
once-daily CIC 320 mcg significantly (P , 0.05 versus 
  placebo) inhibited levels of IL-12 and MCP-1 in sputum 
within 4 hours of administration. Inhibition of IL-12, MCP-1, 
IL1a, IL-6, IL-7, and IL-8 in sputum was observed within 
4 hours of twice-daily administration of CIC 640 mcg 
versus placebo (P , 0.01). After 1 week of treatment with 
twice-daily CIC 640 mcg, interferon (INF)-inducible protein 
10 was significantly (P , 0.001) inhibited compared with 
placebo.12
Once-daily CIC 80 mcg attenuated allergen-induced 
increases in the production of IL-4 and IL-5 in patients with 
mild atopic asthma. The drug also reduced chemokine-
induced T-cell migration versus placebo prior to and 6 hours 
after allergen challenge.13
Several studies have shown that treatment with CIC 
reduced the percentage of eosinophils in induced sputum of 
patients with asthma. CIC (40 and 80 mcg/day) attenuated 
the number of eosinophils in the sputum 8 hours but not 
24 hours after allergen challenge.14 In another study, sputum 
eosinophilia was significantly attenuated with CIC 40 and 
80 mcg/day 24 hours after allergen challenge.15
Effect on eosinophil-cationic-protein release was not 
as consistent, with two studies16,17 showing reduction from 
  pretreatment levels with CIC 400 mcg/day; however, no effect 
was seen with CIC 100 and 1600 mcg in the one study.16 
In another study, CIC 40 mcg/day was found to attenuate 
  allergen-induced reduction in IFN-γ-positive-CD4 T-cells 
24 hours after provocation, although this effect was not seen 
with CIC 80 mcg/day.14
CIC also reduced levels of exhaled nitric oxide (NO) 
in patients with mild to moderate asthma. In a randomized 
double-blind, placebo-controlled, randomized crossover, 
study of 17 patients, exhaled NO levels were measured after 
treatment with CIC 160 mcg once-daily for 4 weeks. Exhaled 
NO difference between CIC and placebo was 47 ppb (95% 
confidence interval [CI]: 15–81 ppb).18 A preliminary study 
suggested CIC produced a greater and more rapid reduction 
in exhaled NO than comparable doses of fluticasone.19
In summary, CIC has significant anti-inflammatory 
effects, which support its clinical efficacy in the studies that 
follow.
Clinical efficacy and safety studies
Ciclesonide versus placebo
A 2008 Cochrane review evaluated randomized parallel or 
crossover studies comparing CIC at different doses with 
placebo.20 Eighteen trials, which included 6343 participants, 
of which 1692 were children, met the review entry criteria. Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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At doses of #100–400 mcg/day in mild to moderate asthma, 
CIC improved lung function, asthma symptoms, and rescue 
inhaler use, compared with placebo. Comparisons of CIC 
at different doses did not yield significant differences in 
lung function. The short duration of these trials precluded 
conclusions regarding the effectiveness of CIC in preventing 
asthma exacerbations.
Table 1 summarizes the key findings in a representative 
sample of trials comparing the efficacy and safety of CIC at 
different doses with placebo.
The US Food and Drug Administration recommended 
dosing was based on review of the above studies. The trial 
by Berger et al specifically demonstrated that CIC in a twice-
daily dosing regimen was superior at improving pulmonary 
function and controlling disease symptoms than the CIC 
at twice the dose on a once-daily dosing regimen and was 
superior to placebo.25 This trial supported the presence of a 
dose frequency–dependent effect of the ICS on lung func-
tion and led to approval only for BID dosing in the USA.
Bateman et al investigated the effectiveness of CIC to 
reduce oral corticosteroid use in patients with severe, persistent 
asthma who were steroid dependent.26 Patients received CIC 
delivered via HFA-MDI at 320 mcg twice-daily, CIC delivered 
via HFA-MDI at 640 mcg twice-daily, or placebo (all received 
at 8 am and 8 pm). At study end, CIC 640 mcg/day and CIC 
1280 mcg/day significantly reduced prednisone use whereas 
steroid use increased in the placebo group. Furthermore, 
30% of patients in the CIC groups were able to discontinue 
prednisone entirely and significantly fewer patients in the CIC 
groups required an increase in prednisone dose compared with 
placebo. These results suggest that CIC significantly reduces 
the need for oral corticosteroids in patients with severe, 
  persistent asthma and maintains asthma control.
In summary, CIC has been demonstrated to be an effective 
ICS for patients with mild, moderate, and severe persistent 
asthma. Additionally, it can be beneficial in reducing oral 
corticosteroid requirements in OCS-dependent asthma 
patients.
Comparisons with other inhaled 
corticosteroids
A 2009 Cochrane review assessed the efficacy and adverse 
effects of CIC compared with those of other ICSs in the 
management of chronic asthma.27 Randomized parallel 
or crossover studies were reviewed. Studies comparing 
CIC with other steroids both at nominally equivalent dose 
or lower doses of CIC were included. Twenty-one trials 
involving 7243 participants (children and adults) were 
included. Equivalent daily doses of CIC and beclomethasone 
diproprionate (BDP) or BUD demonstrated similar results 
for peak expiratory flow rates. However, forced vital capacity 
(FVC) was higher with CIC, while forced expiratory volume 
(FEV1) data were inconsistent. When CIC was compared 
with equivalent doses of FP, FEV1, FVC, and peak expiratory 
Table 1 A representative sample of trials evaluating the efficacy of ciclesonide (CIC) in the treatment of asthma in adults and 
adolescents
Trial Study design 
(n of patients)
Pulmonary function Asthma symptom score Rescue medication use
Chapman et al21 12 wk, DB, R, PG, PC, 329 pts,  
CiC 160, CiC 640, vs PL
PeF and Fev1 did not change  
with either CiC dosea,  
decreased with PL
worsened with PL, stable  
with either CiCa dose
increased in PL vs both CiC 
groupsa,b
Adachi et al22 8 wk, PC, DB, PG, CIC 80 (78), CIC  
160 (71), CIC 320 (83), vs PL (79)
PeF did not change with any  
CiC dose, decreased with PLa
worsened with PL, stable  
with all CiC doses
Decreased in all CiC groups 
vs PL
Langdon et al23 12 wk, R, PC, CIC 80 (120), 320  
(115), vs PL (125)
PeF maintained in CiC groups, 
decreased in PLa Fev1 increased 
in CiC groups,a,c slight decrease  
in PL (P = 0.54)
worsened with PL, stable  
with all CiC dosesa
Stable in CiC groups, 
increased in PL
Pearlman et al24 12 wk, MC, DB, R, PG, PC, CiC 80 
(257), CIC 160 (250), CIC 320 (255), 
PL (249)
Fev1 and PeF improved in all  
CiC groups vs PL
improved with all  
CiC groups vs PL
Reduced in CiC groups, 
increased in PL
Berger et al25 16 wk, MC, MN, DB, PG, PC, R,  
CIC 80 BID (170), CIC 160 QD 
(173), CIC 80 BID/CIC 160 QD  
(171) PL (177)
Fev1 improved in all CiC groups, 
greatest improvement in CiC  
80 BiD. AM PeF improved  
in all CiC groupsa vs PL
improved in all Rx groups, 
CiC 80 groups improved 
vs PL
Decreased in all treatment 
groups, greatest reduction  
in CiC groups
Abbreviations: DB, double blind; R, randomized; PG, parallel group; PC, placebo controlled; MC, multicenter; MN, multinational; AM, morning; PL, placebo; wk, week.
Notes: aNo significant difference between CIC groups; bno change from baseline; cversus baseline; only statistically significant differences are reported to P , 0.05, unless 
otherwise noted; all reported doses are exactuator and in micrograms; all medication was delivered via hydrofluoroalkane metered dose inhaler; there were no significant 
adverse events noted in any of the studies.Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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flow (PEF) did not differ significantly. Candidiasis was 
less frequent with CIC, although there were no significant 
differences in other side effects. When lower doses of CIC 
were compared with BDP or BUD, the difference in FEV1 
did not reach significance. Other lung function outcomes did 
not demonstrate significant differences between treatments. 
Adverse events occurred with similar frequency between 
CIC and BDP/BUD. In three studies, CIC was compared with 
FP at half the nominal dose and FEV1 was not significantly 
different but was also not equivalent between the treatments 
(per protocol: –0.05 L, 95% CI –0.11–0.01).
Table 2 A representative sample of trials comparing the efficacy and safety of ciclesonide (CIC) to other inhaled corticosteroids
Trial Study design  
(number of patients)
Pulmonary function Asthma  
symptom score
Rescue  
medication use
Buhl et al28 12 wk, MC, R, DB, DD, PG  
study CIC 160 qd (266)b vs  
FP 88 BID (263)b
PeF and Fev1 improved  
significantly in both groupsa
improved in both  
treatment groups
Not different between 
treatment groups
Magnussen et al29 12 wk, DB, DD, PG, R,  
CIC 80 qd (278)b, CiC 160  
qd (271)b or FP 88 BID (259)b
Fev1 improved significantly  
in all Rx groupsa 
Site measured PeF improved  
significantly in all Rx groups
improved in all  
treatment groupsa
Decreased to similar  
extent in all  
treatment groupsa
Boulet et al30 12 wk, R, OL, PG, CiC 320  
qd (234)b, FP 200 BID (240)c
Fev1 improved significantly  
in both Rx groupsa  
AM PeF improved  
significantly in CIC group
improved in both  
groupsa
Decreased in both  
treatment groupsa
Bateman et al31 24 wk, R, MC, OL, PG,  
CIC 320 BID (255)b,  
FP 330 BID (273)b
Fev1 maintained in both  
Rx groupsg 
PEF improved significantly  
in both Rx groupsa
improved in both  
Rx groupsa
Decreased in both  
Rx groups
Niphadkar et al32 12 wk, R, MC, PG, DB, DD,  
of CIC with OL BUD BID,  
CIC 160 QAM (139)b,  
CIC 160 QPM (131)b or  
BUD 200 BID (133)b
Fev1 maintained in all  
Rx groupsa 
No significant differences  
found among Rx groups  
for PEF
Maintained in all  
Rx groupsa
Maintained in all  
Rx groups vs baselinea
Hansel et al33 12 wk, MC, R, DB for CIC,  
OL for BUD, of CIC 80 qd (182)b,  
CIC 320 qd (195)b vs BUD 200  
BID (177)f
Fev1 improved in all groups  
at 12 wks. No significant difference  
between CiC groups. 
PeF improved in all groupsa
improved in all  
Rx groups
Decreased in  
all groups
Boulet et al34 12 wk MC, R, DB, DD, PG study,  
CIC 320 qd (179)b, vs BUD  
320 qd (180)d
Change in Fev1 was similar  
in both Rx groups. 
Mean PeF did not change  
in either Rx group
No significant  
difference in scores  
between Rx groups
Decreased in  
CiC group
Ukena et al35 12 wk DB, DD, R, PG study,  
CIC 320 qd (198)b vs  
BUD 400 qd (201)d
Fev1 improved in both Rx groups, CiC  
demonstrating superiority over BUD.  
PeF improved in both Rx groups,  
CiC showed greater  
increase than BUD
improved in both  
Rx groupsa
Decreased in both  
Rx groupsa
vermeulen et al36 12 wk MC, R, DB, DD, PG,  
CiC 320 qdb (272) vs  
BUD 800 qd (131)d
Fev1 increased in both Rx groups.a  
AM and PM PEF increased significantly  
only in CiC group.
improved in both  
Rx groupsa
Decreased in both  
Rx groups
Notes: Only statistically significant differences are reported to P , 0.05, unless otherwise noted; all reported doses are ex-actuator and in micrograms; ano statistically 
significant difference noted between the treatment groups; bdelivered via HFA-M; cdelivered dry powder via inhaler (diskus); ddelivered via Turbohaler; fdelivered via dry 
powder inhaler; gno significant change seen from baseline to study end.
Abbreviations: AM, morning; DB, double blind; DD, double dummy; R, randomized; PG, parallel group; PC, placebo controlled; MC, multicenter; OL, open label; CiC, 
Ciclesonide; FP, Fluticasone propionate; BUD, Budesonide; AE, adverse event; wk, week; Rx, treatment; qd, once-daily; BID, twice-daily; vs, versus; QAM, every morning; 
QPM, every evening; PEF, peak expiratory flow; FEV1, forced expired volume in one second.
Table 2 reviews the key findings in a representative sample 
of trials comparing CIC to FP and BUD in adults and adoles-
cents with mild, moderate, and severe persistent asthma. Of 
note, the majority of adverse events (AEs) were assessed as 
unrelated to study medication and were mild to moderate in 
intensity. No significant lab abnormalities were noted. In the 
Buhl et al28 study, three patients receiving FP developed oral 
AEs, including voice alteration or oral candidiasis. In the Boulet 
et al30 and Bateman et al31 studies, significantly more patients 
treated with FP developed local oral AEs. Hansel et al33 noted a 
significant decrease in urinary cortisol concentration in patients Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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receiving BUD. Ukena et al35 noted four AEs (cough, headache, 
dyspnea, and voice   alteration) potentially related to CIC.
Effect of ciclesonide on HPA axis
Dose-related adverse effects have been described for ICSs, 
especially in patients with moderate-to-severe asthma 
who may require higher doses to achieve asthma control. 
Systemic adverse effects that have been reported include 
osteoporosis, growth suppression, cataracts, glaucoma, and 
adrenal insufficiency, while local adverse effects include 
hoarseness, dysphonia, pharyngitis, and oral candidasis.
HPA axis
Lipworth evaluated the potential effects of CIC therapy 
on the dynamic cortisol response to sequential low- and 
high-dose cosyntropin stimulation in adults with mild-to-
moderate persistent asthma.37 In a double-blind, placebo-
controlled, 12-week study, 164 patients were randomized to 
placebo, 320 mcg CIC once-daily, 320 mcg CIC twice-daily 
(all CIC doses delivered via HFA-MDI), and 440 mcg FP 
twice-daily delivered via CFC-MDI, all doses ex-actuator. 
Patients had normal HPA-axis function at screening and 
had not used systemic corticosteroids within 6 months of 
screening or inhaled or intranasal corticosteroids within 
2 months of screening.
CIC at doses up to 640 mcg/day does not affect sensitive 
markers of adrenal function. CIC did not produce any signifi-
cant suppression of either basal cortisol levels or the response 
to cosyntropin stimulation, with results almost identical to the 
placebo group. In contrast, the FP group showed significant 
suppression of 24-hour-urinary-free cortisol levels and on 
high-dose cosyntropin stimulation compared to the placebo 
group. The differences between CIC groups and FP were 
statistically significant. Thus, CIC may result in less adrenal 
suppression than FP.
Local effects
Oral candidasis occurred in 22.0% of FP group compared 
with 2.4% in the combined CIC groups. Hoarseness 
occurred at a rate of 7.3% in the FP group and 2.4% in the 
combined CIC groups.37
Systemic effects
Other potential systemic effects of inhaled corticosteroids 
include decreased bone mineral density, cataract formation, 
glaucoma, and growth suppression.
Derom looked at markers of bone metabolism in a 
  randomized, double-blind, double-dummy, placebo-controlled, 
five-period crossover study conducted at two   centers.38 
CIC 160, CIC 320 BID, FP 250 BID, FP 500 BID, or placebo 
were compared, which were administered in addition to a 
maintenance dose of CIC 160 qd. No significant differences 
were noted after any CIC treatment compared with placebo 
for any bone formation marker, which included N-terminal 
propeptide of type 1 procollagen (P1NP), alkaline phos-
phatase (AP), and serum osteocalcin. FP 1000 caused signifi-
cant decreases in P1NP (P = 0.0126) and serum osteocalcin 
levels (P = 0.0054) compared with placebo. The clinical 
significance of these findings is not clear.
Chylack demonstrated that treatment with CIC 640 mcg/day 
or beclomethasone dipropionate 640 mcg/day for 1 year had 
a minimal impact on lenticular opacity development and/or 
progression.39
A 52-week, multicenter, double-blind, randomized, 
placebo-controlled, parallel-group study was conducted 
to assess the effect of CIC on growth rate in 609 pediatric 
patients aged 5–8.5 years. Patients were randomized to 
CIC 40 mcg, 160 mcg, or placebo once-daily. Growth was 
measured during baseline, treatment, and follow-up periods. 
There was no difference in efficacy measures, but conclusive 
results could not be drawn because compliance could not 
be assured.3
These studies suggest that CIC has minimal systemic 
adverse effects.
Conclusion
CIC is a nonhalogenated ICS, available as a HFA-MDI in 
two strengths, 80 mcg/actuation and 160 mcg/actuation, 
administered twice-daily. Several properties, including 
its prodrug structure, high lipid affinity, and glucocorti-
coid receptor–binding affinity of the active drug des-CIC, 
low oral deposition, low oral bioavailability, extensive 
peripheral distribution in the lung, high protein binding, 
and extensive first-pass metabolism, favor higher thera-
peutic efficacy and limited systemic exposure. CIC 
has significant anti-  inflammatory effects that also con-
tribute to its clinical efficacy. Studies have shown that 
CIC improves lung function, asthma symptoms, and rescue 
inhaler use, compared with placebo in patients with mild, 
moderate, and severe persistent asthma. CIC also significantly 
reduces the need for oral corticosteroids in patients with 
severe persistent asthma and maintains asthma control. CIC 
is at least as effective as FP, BUD, and beclomethasone pro-
pionate in maintaining pulmonary function, asthma control, 
and improving symptoms. Most significantly, CIC at doses 
up to 640 mcg/day does not   suppress either basal cortisol 
levels or the response to cosyntropin stimulation. CIC may Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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cause less adrenal suppression than FP.   Studies evaluating 
growth rate, lens opacity development, and markers of bone 
metabolism suggest that CIC’s systemic effects are minimal. 
The unique contribution of CIC in the treatment of asthma 
lies in its excellent safety profile.
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